From: oncodaily.com For patients with hormone receptor–positive metastatic breast cancer, the therapeutic landscape has expanded dramatically. Molecularly selected therapies targeting ESR1, PIK3CA and the AKT pathway have created additional endocrine-based options.
From: oncodaily.com For patients with hormone receptor–positive metastatic breast cancer, the therapeutic landscape has expanded dramatically.
Molecularly selected therapies targeting ESR1, PIK3CA and the AKT pathway have created additional endocrine-based options.
Perhaps most importantly for HER2-low disease, antibody-drug conjugates have changed the meaning of HER2 expression itself.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
From: oncodaily.com For patients with hormone receptor–positive metastatic breast cancer, the therapeutic landscape has expanded dramatically. Molecularly selected therapies targeting ESR1, PIK3CA and the AKT pathway have created additional endocrine-based options. Perhaps most importantly for HER2-low disease, antibody-drug conjugates have changed the meaning of HER2 expression itself.
CDK4/6 inhibitors transformed first-line treatment.
Open the app view to save this story, compare related coverage, and continue from the same source.